Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500445 | 0.90 | TRIM24 (0.36) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL5243327 | 0.67 | TRIM24 (0.35) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL9171769 | 0.65 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL5247941 | 0.65 | TRIM24 (0.33) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL16099106 | 0.63 | TRIM24 (0.41) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL307414 | 0.63 | — | — | |
| SCHEMBL13232096 | 0.63 | MEN1 (0.36) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL119955 | 0.62 | — | — | |
| SCHEMBL7981543 | 0.62 | — | — | |
| SCHEMBL15565627 | 0.61 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069362-A1 | Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ZHANG XUQING | 2009-03-12 | — | — | US | disclosed |
| US-7452914-B2 | Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-20060020018-A1 | Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020018-A1 | Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ESR2, ESR1, ESRRA | MEN1 1829/4885CYP2C9 934/4885KMT2A 3725/4885 |
| US-20090069362-A1 | Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | ESR2, ESR1, ESRRA | MEN1 1829/4885CYP2C9 934/4885KMT2A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.